Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease
Journal of Parkinson’s Disease · 2024
DOI: 10.3233/jpd-230408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parkinson’s Disease, 2024. Verfasst von Luca Jannik Braunger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, MicroRNAs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mutations in the Leucine Rich Repeat Kinase 2 gene are highly relevant in both sporadic and familial cases of Parkinson’s disease. Specific therapies are entering clinical trials but patient stratification remains challenging. Dysregulated microRNA expression levels have been proposed as biomarker candidates in sporadic Parkinson’s disease.
Objective
In this proof-of concept study we evaluate the potential of extracellular miRNA signatures to identify LRRK2-driven molecular patterns in Parkinson’s disease.
Methods
We measured expression levels of 91 miRNAs via RT-qPCR in ten individuals with sporadic Parkinson’s disease, ten LRRK2 mutation carriers and eleven healthy controls using both plasma and cerebrospinal fluid. We compared miRNA signatures using heatmaps and t-tests. Next, we applied group sorting algorithms and tested sensitivity and specificity of their group predictions. Results: miR-29c-3p was differentially expressed between LRRK2 mutation carriers and sporadic cases, with miR-425-5p trending towards significance. Individuals clustered in principal component analysis along mutation status. Group affiliation was predicted with high accuracy in the prediction models (sensitivity up to 89%, specificity up to 70%). miRs-128-3p, 29c-3p, 223-3p, and 424-5p were identified as promising discriminators among all analyses.
Conclusions
LRRK2 mutation status impacts the extracellular miRNA signature measured in plasma and separates mutation carriers from sporadic Parkinson’s disease patients. Monitoring LRRK2 miRNA signatures could be an interesting approach to test drug efficacy of LRRK2-targeting therapies. In light of small sample size, the suggested approach needs to be validated in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany.
Zitieren
APA
Braunger, L. J., Knab, F., & Gasser, T. (2024). Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-230408
Vancouver
Braunger LJ, Knab F, Gasser T. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease. Journal of Parkinson’s Disease. 2024. doi:10.3233/jpd-230408
BibTeX
@article{Braunger2024,
author = {Braunger, Luca Jannik and Knab, Felix and Gasser, Thomas},
title = {Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease},
journal = {Journal of Parkinson’s Disease},
year = {2024},
doi = {10.3233/jpd-230408}
}
EUVIMED